TrialThe Lancet. Infectious diseases2020

Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial.

Kathryn E Stephenson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.